Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Vitamin D levels and the risk of prostate cancer and prostate cancer mortality

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{15e5b95ce34446f8b221ab7fad835f3c,
title = "Vitamin D levels and the risk of prostate cancer and prostate cancer mortality",
abstract = "BACKGROUND: Vitamin D has a role in bone turnover and potentially bone-metastatic spread of prostate cancer (PCa). The aim of this observational study was to address the association between levels of serum vitamin D, diagnosis of PCa and subsequent mortality in men who underwent a biopsy of the prostate.METHODS: All men who underwent prostatic biopsy in the Danish PCa Registry (DaPCaR) and who had a serum vitamin D measurement during the period 2004 to 2010 (n = 4,065) were identified. Men were categorized by clinical cut-offs based on seasonally adjusted serum vitamin D levels in <25 (deficient), 25-50 (insufficient), 50-75 (sufficient) and >75 nmol/L (high) serum vitamin D. Logistic regression model for association between vitamin D and risk of PCa diagnosis and multivariate survival analyses were applied.RESULTS: No association between serum vitamin D and risk of PCa was found. Overall survival was lowest for serum vitamin D deficiency and a significantly higher PCa specific mortality (HR: 2.37, 95{\%}CI: 1.45-3.90, p < .001) and other cause mortality (HR: 2.08, 95{\%}CI: 1.33-3.24, p = .001) was found for PCa patients with serum vitamin D deficiency compared to serum vitamin D sufficiency.CONCLUSION: No association was found between serum vitamin D categories and risk of PCa in men who underwent biopsy of the prostate. Men with PCa and serum vitamin D deficiency had a higher overall and PCa specific mortality compared to men with a sufficient level of serum vitamin D.",
keywords = "epidemiology, mortality, Prostatic neoplasms, risk, Vitamin D",
author = "Stroomberg, {Hein Vincent} and Vojdeman, {Fie Juhl} and Madsen, {Christian Medom} and Helgstrand, {John Thomas} and Peter Schwarz and Anne-Marie Heegaard and Anja Olsen and Anne Tj{\o}nneland and {Struer Lind}, Bent and Klaus Brasso and J{\o}rgensen, {Henrik L{\o}vendahl} and R{\o}der, {Martin Andreas}",
year = "2020",
month = "10",
day = "24",
doi = "10.1080/0284186X.2020.1837391",
language = "English",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",

}

RIS

TY - JOUR

T1 - Vitamin D levels and the risk of prostate cancer and prostate cancer mortality

AU - Stroomberg, Hein Vincent

AU - Vojdeman, Fie Juhl

AU - Madsen, Christian Medom

AU - Helgstrand, John Thomas

AU - Schwarz, Peter

AU - Heegaard, Anne-Marie

AU - Olsen, Anja

AU - Tjønneland, Anne

AU - Struer Lind, Bent

AU - Brasso, Klaus

AU - Jørgensen, Henrik Løvendahl

AU - Røder, Martin Andreas

PY - 2020/10/24

Y1 - 2020/10/24

N2 - BACKGROUND: Vitamin D has a role in bone turnover and potentially bone-metastatic spread of prostate cancer (PCa). The aim of this observational study was to address the association between levels of serum vitamin D, diagnosis of PCa and subsequent mortality in men who underwent a biopsy of the prostate.METHODS: All men who underwent prostatic biopsy in the Danish PCa Registry (DaPCaR) and who had a serum vitamin D measurement during the period 2004 to 2010 (n = 4,065) were identified. Men were categorized by clinical cut-offs based on seasonally adjusted serum vitamin D levels in <25 (deficient), 25-50 (insufficient), 50-75 (sufficient) and >75 nmol/L (high) serum vitamin D. Logistic regression model for association between vitamin D and risk of PCa diagnosis and multivariate survival analyses were applied.RESULTS: No association between serum vitamin D and risk of PCa was found. Overall survival was lowest for serum vitamin D deficiency and a significantly higher PCa specific mortality (HR: 2.37, 95%CI: 1.45-3.90, p < .001) and other cause mortality (HR: 2.08, 95%CI: 1.33-3.24, p = .001) was found for PCa patients with serum vitamin D deficiency compared to serum vitamin D sufficiency.CONCLUSION: No association was found between serum vitamin D categories and risk of PCa in men who underwent biopsy of the prostate. Men with PCa and serum vitamin D deficiency had a higher overall and PCa specific mortality compared to men with a sufficient level of serum vitamin D.

AB - BACKGROUND: Vitamin D has a role in bone turnover and potentially bone-metastatic spread of prostate cancer (PCa). The aim of this observational study was to address the association between levels of serum vitamin D, diagnosis of PCa and subsequent mortality in men who underwent a biopsy of the prostate.METHODS: All men who underwent prostatic biopsy in the Danish PCa Registry (DaPCaR) and who had a serum vitamin D measurement during the period 2004 to 2010 (n = 4,065) were identified. Men were categorized by clinical cut-offs based on seasonally adjusted serum vitamin D levels in <25 (deficient), 25-50 (insufficient), 50-75 (sufficient) and >75 nmol/L (high) serum vitamin D. Logistic regression model for association between vitamin D and risk of PCa diagnosis and multivariate survival analyses were applied.RESULTS: No association between serum vitamin D and risk of PCa was found. Overall survival was lowest for serum vitamin D deficiency and a significantly higher PCa specific mortality (HR: 2.37, 95%CI: 1.45-3.90, p < .001) and other cause mortality (HR: 2.08, 95%CI: 1.33-3.24, p = .001) was found for PCa patients with serum vitamin D deficiency compared to serum vitamin D sufficiency.CONCLUSION: No association was found between serum vitamin D categories and risk of PCa in men who underwent biopsy of the prostate. Men with PCa and serum vitamin D deficiency had a higher overall and PCa specific mortality compared to men with a sufficient level of serum vitamin D.

KW - epidemiology

KW - mortality

KW - Prostatic neoplasms

KW - risk

KW - Vitamin D

U2 - 10.1080/0284186X.2020.1837391

DO - 10.1080/0284186X.2020.1837391

M3 - Journal article

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

ER -

ID: 61115398